Latest News and Press Releases

ZyVersa provides regulatory and product support for Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a patient with ApoCII amyloidosis.

Site initiation for Phase 2a DKD trial marks a key milestone for ZyVersa, and for development of VAR 200, a first-in-class treatment for kidney disease.

WESTON, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...

Parasol group recommended reduction in proteinuria over 24 months as a surrogate endpoint for full approval of FSGS drugs.

ZyVersa looks forward to meeting with investors and potential collaborators at JPM 2025 to discuss our technology, pipeline, and development milestones.

ZyVersa announces progress toward achieving key near-term development milestones and Q3-2024 financials.

ZyVersa welcomes one-on-one meetings at the HCW Kidney Conference on July 15, 2024.

ZyVersa is on track to achieve key development milestones over the next 3 quarters.

To learn more about ZyVersa's Inflammasome ASC Inhibitor and Renal Pipelines, schedule a one-on-one meeting on 2024 BIO International Conference's Portal.

Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024.Inflammasome ASC Inhibitor IC 100 preclinical program...